Glaucoma Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The glaucoma diagnostics market size is expected to grow from USD 2.49 billion in 2025 to USD 2.63 billion in 2026 and is forecast to reach USD 3.46 billion by 2031 at 5.62% CAGR over 2026-2031. This report is Segmented Into Product Type (Diagnostic Instruments, Diagnostic Imaging Devices, and Consumables), Technology (Tonometry, Ophthalmoscopy, and More), Patient Demographics (Adults, Geriatric, and Pediatric), Test Category (Screening Tests, and More), End User (Hospitals, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Glaucoma Diagnostics Market Trends and Insights

Rising Glaucoma Prevalence and Earlier Case Finding

Global glaucoma cases increased from 4.1 million in 1990 to 7.6 million in 2021, while the age-standardized disability-adjusted life-year rate reached 33.1 per 100,000 population in 2021. In 2020, at least 43 million cases of primary open-angle glaucoma remained undetected, with Africa and Asia bearing a greater burden of missed cases than Europe. This undiagnosed population creates sustained demand for screening pathways that guide patients toward a confirmed diagnosis. Glaucoma caused bilateral blindness in 3.6 million people and moderate-to-severe visual impairment in 4.1 million people in 2020, accounting for 8.4% of global blindness. Therefore, the glaucoma diagnostics market relies on both advanced hospital-based equipment and accessible first-line tools to identify individuals who have not yet entered specialist care. The expected contribution of myopia to the future disease burden also indicates that demand is not limited to countries with the oldest populations.

Aging, Imaging, and Connected Monitoring Workflows

Glaucoma prevalence increases from 1 in 200 people at age 40 to 1 in 8 people at age 80, extending the period during which many patients require observation and testing. Individuals diagnosed in later middle age can undergo OCT and visual field testing for many years, supporting the recurring use of existing equipment. Germany’s clinical guideline recommends glaucoma risk assessments from age 40, although statutory insurance coverage remains limited to individuals with specific risk factors.

OCT platforms are expanding their role by integrating structural imaging, vascular information, and software-based review into a single session. The glaucoma diagnostics market benefits when clinicians can review imaging and visual field results together, enabling them to assess changes over time while reducing reliance on disconnected records. Automated alignment, portable imaging, and remote review also make diagnostic activities more practical in primary care and tele-ophthalmology settings, where specialist capacity remains limited.

Capital Costs and Uneven Diagnostic Capacity

Premium OCT and multimodal imaging systems cost between USD 30,000 and more than USD 100,000, excluding service, software, and calibration expenses. These costs limit procurement by smaller community centers, particularly in areas with a high burden of undiagnosed disease. Limited capital budgets must cover both the equipment purchase and ongoing expenses for servicing, licensing, calibration, and staff training. Foreign currency exposure can further constrain affordability, as many high-specification systems are priced in USD or EUR. Portable tonometers and fundus cameras improve access; however, they cannot replace the structural imaging and functional testing required for confident staging and follow-up. Therefore, the glaucoma diagnostics market must address the needs of facilities with varying budgets, staffing levels, and service capabilities. Suppliers that provide durable equipment, transparent maintenance arrangements, and scalable training programs can reduce a key adoption barrier while maintaining clinical standards.

Other drivers and restraints analyzed in the detailed report include:

• Community Programs and Primary-Care Access
• AI-Enabled Interpretation and Screening Quality
• Workforce Limits, Variable Testing, and AI Governance

Segment Analysis

Diagnostic instruments accounted for 56.23% of the glaucoma diagnostics market share in 2025. Tonometers, slit lamps, and gonioscopy equipment remain essential first-line tools in specialist and primary care workflows. Their long service life and relatively straightforward maintenance requirements support consistent use, particularly among providers that require reliable equipment for high volumes of routine examinations and cannot immediately replace established examination methods with more complex imaging technologies.

Many practices rely on these instruments for initial intraocular pressure, angle, and optic disc assessments. These measurements provide the practical information needed to determine whether a patient requires observation, imaging referral, or further evaluation by a glaucoma specialist. Although demand is mature in well-equipped markets, these instruments remain necessary before clinicians interpret imaging findings. They also provide a practical option for clinics that cannot support a full multimodal diagnostic platform.

Consumables, including probe covers, visual field materials, and maintenance items, are expected to generate smaller but recurring revenue streams. This recurring demand is expected to increase the relevance of service contracts in the glaucoma diagnostics market, enabling suppliers to support equipment uptime through scheduled calibration, replacement accessories, and practical user assistance throughout the extended period during which clinics retain their core examination tools. Overall, this product group is expected to provide a broad foundation for routine ophthalmic care, allowing providers to maintain familiar first-line examination methods while adopting imaging technologies when clinical pathways or referral patterns require more detailed assessments.

Diagnostic imaging devices are projected to grow at a CAGR of 6.27% through 2031. This category includes optical coherence tomography (OCT) systems, scanning laser ophthalmoscopes, and fundus cameras. These systems integrate structural measurements, retinal visualization, and increasingly, vascular assessment within a connected workflow. In September 2025, Topcon introduced Triton2 and IMAGEnet7 to the European market, adding wide-field OCT angiography, true-color imaging, anterior-segment analysis, and Smart Denoise technology. These systems enable providers to consolidate multiple clinical tasks into fewer instruments. They also support more detailed follow-up during repeat testing, as clinicians can compare current images with earlier structural findings and use the same platform to document whether suspected changes warrant further assessment. As of 2026, the glaucoma diagnostics industry is shifting toward platforms that support both initial evaluation and ongoing monitoring. However, imaging suppliers must demonstrate reliable clinical value compared with lower-cost standalone instruments. Their advantage is strongest in settings where providers require more comprehensive information from each visit. A single imaging platform can support baseline assessments, confirmation of suspected disease, comparison of structural findings during follow-up appointments, and clearer patient discussions when clinicians need to explain the need for continued monitoring.

Optical coherence tomography (OCT) accounted for 38.73% of the glaucoma diagnostics market in 2025. OCT supports structural assessment by measuring the retinal nerve fiber layer and ganglion cell complex, while OCT angiography adds vascular information within the same imaging workflow. Established normative databases reinforce OCT’s role in routine clinical decision-making, and serial scans help clinicians identify subtle structural changes over time. As a result, OCT plays an important role in both diagnosis and long-term surveillance, particularly when practices monitor patients from initial risk assessment and disease confirmation through treatment review and potential progression assessment. The glaucoma diagnostics market maintains a strong OCT foundation because the technology supports multiple stages of care. However, image quality, acquisition consistency, and clinician interpretation remain critical to generating useful results. Suppliers can improve usability in busy practices by integrating data review with patient records. Systems that guide staff through consistent measurement protocols at each visit also support comparable follow-up scans and enhance their practical value.

Visual field testing is forecast to expand at a CAGR of 6.85% through 2031. Functional testing remains essential because structural measurements alone cannot fully characterize a patient’s visual impairment. The German guideline identifies tonometry and optic disc assessment as core elements of glaucoma risk evaluation for individuals aged 40 years and older. Carl Zeiss Meditec announced a collaboration with Envision Health Technologies in June 2026 to develop gamified, VR-based visual field testing. The collaboration aims to improve access and patient adherence across different care settings. VR-based approaches may reduce the practical barriers associated with conventional clinic-based perimetry by enabling testing in more locations and helping patients complete repeat assessments with fewer travel and scheduling challenges. Tonometry remains the standard initial screening method for intraocular pressure, while gonioscopy and ophthalmoscopy retain specialist roles. Together, these technologies provide the glaucoma diagnostics market with a balance between accessible screening and detailed diagnostic confirmation. This balance remains important because pressure measurement, structural imaging, and functional testing each address distinct clinical questions during glaucoma assessment.

Complete Report Scope:

• By Product Type
  • Diagnostic Instruments
  • Diagnostic Imaging Devices
  • Consumables
• By Technology
  • Tonometry
  • Ophthalmoscopy
  • Visual Field Testing
  • Optical Coherence Tomography
  • Others
• By Patient Demographics
  • Adults
  • Geriatrics
  • Pediatrics
• By Test Category
  • Screening Tests
  • Diagnostic Tests
  • Progression-Monitoring Tests
• By End User
  • Hospitals
  • Ophthalmology Clinics
  • Diagnostic Centers
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held a 38.62% share of the glaucoma diagnostics market in 2025, supported by reimbursed OCT use, active screening programs, and a dense network of academic ophthalmology centers. The Michigan SIGHT program demonstrated that telemedicine and care navigation can improve follow-up in underserved communities, while MI-SIGHT 2 began enrollment in December 2025. An implementation study at Federally Qualified Health Centers is comparing OCT-only and combined imaging protocols for AI-based screening. These initiatives support platforms that integrate primary care, remote review, and specialist confirmation. Canada’s provincial health systems are evaluating OCT funding models, while Mexico’s mixed public-private healthcare system continues to drive demand for entry-level tonometry and fundus photography.

Asia-Pacific is forecast to grow at a CAGR of 10.44% through 2031, representing the fastest regional growth rate in the glaucoma diagnostics market. East Asia is expected to record a 50.5% increase in open-angle glaucoma prevalence between 2024 and 2060. Major public hospitals in China are modernizing ophthalmology departments with multimodal imaging, India is expanding telemedicine-based screening networks, and Japan’s aging population continues to support investment in clinical equipment. South Korea and Australia are early adopters of AI-integrated workflows. The region is important both for high-volume adoption and for service models that operate beyond specialist hospitals.

Europe held a significant market share in 2025, supported by established ophthalmology networks, reimbursement-backed imaging, and regional manufacturers. Germany’s guideline framework supports risk assessment from age 40, although statutory coverage remains limited to individuals with defined risk factors. EU medical device requirements may favor suppliers with documented processes and established clinical evidence. The Middle East, Africa, and South America face high unmet needs; however, capital and workforce constraints limit deployment. Sub-Saharan Africa is projected to experience an 86.3% increase in undetected primary open-angle glaucoma by 2040.

List of Companies Covered in this Report:

• Alcon
• AMETEK, Inc.
• Bausch Health
• Canon
• Carl Zeiss
• EssilorLuxottica
• HAAG-Streit
• Halma
• Heidelberg Engineering
• Keeler
• Danaher
• LKC Technologies, Inc.
• Nidek
• Optopol Technology Sp. z o.o.
• Optovue Incorporated
• Reichert
• Revenio Group Plc
• Topcon
• Visionix
• Ziemer Group

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support